Oppenheimer Asset Management Inc. decreased its holdings in Repligen Co. (NASDAQ:RGEN - Free Report) by 16.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 17,567 shares of the biotechnology company's stock after selling 3,418 shares during the period. Oppenheimer Asset Management Inc.'s holdings in Repligen were worth $2,529,000 as of its most recent SEC filing.
Other hedge funds have also recently modified their holdings of the company. Amalgamated Bank increased its holdings in Repligen by 1.0% in the 4th quarter. Amalgamated Bank now owns 25,114 shares of the biotechnology company's stock worth $3,615,000 after buying an additional 238 shares in the last quarter. Keeler Thomas Management LLC grew its stake in shares of Repligen by 68.9% in the fourth quarter. Keeler Thomas Management LLC now owns 8,979 shares of the biotechnology company's stock worth $1,294,000 after acquiring an additional 3,662 shares during the period. Handelsbanken Fonder AB raised its holdings in shares of Repligen by 8.9% during the fourth quarter. Handelsbanken Fonder AB now owns 14,633 shares of the biotechnology company's stock valued at $2,106,000 after purchasing an additional 1,200 shares during the last quarter. Global Retirement Partners LLC lifted its position in Repligen by 54.0% during the fourth quarter. Global Retirement Partners LLC now owns 368 shares of the biotechnology company's stock valued at $53,000 after purchasing an additional 129 shares during the period. Finally, New York State Common Retirement Fund lifted its position in Repligen by 2.5% during the fourth quarter. New York State Common Retirement Fund now owns 581,442 shares of the biotechnology company's stock valued at $83,693,000 after purchasing an additional 14,398 shares during the period. Hedge funds and other institutional investors own 97.64% of the company's stock.
Repligen Price Performance
NASDAQ:RGEN traded up $5.03 during trading hours on Thursday, hitting $162.70. 268,230 shares of the stock traded hands, compared to its average volume of 602,980. The stock has a 50 day moving average price of $156.74 and a 200 day moving average price of $148.54. The company has a quick ratio of 8.76, a current ratio of 10.44 and a debt-to-equity ratio of 0.26. The company has a market cap of $9.12 billion, a price-to-earnings ratio of -319.05, a price-to-earnings-growth ratio of 4.54 and a beta of 0.99. Repligen Co. has a 1 year low of $113.50 and a 1 year high of $203.13.
Repligen (NASDAQ:RGEN - Get Free Report) last released its earnings results on Thursday, February 20th. The biotechnology company reported $0.44 earnings per share for the quarter, beating analysts' consensus estimates of $0.41 by $0.03. Repligen had a negative net margin of 4.64% and a positive return on equity of 4.21%. The company had revenue of $167.55 million for the quarter, compared to analysts' expectations of $167.58 million. Sell-side analysts forecast that Repligen Co. will post 1.72 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have weighed in on RGEN shares. Canaccord Genuity Group initiated coverage on shares of Repligen in a research note on Tuesday, December 17th. They set a "hold" rating and a $165.00 target price for the company. Wolfe Research initiated coverage on Repligen in a research report on Thursday, November 14th. They set a "peer perform" rating for the company. JPMorgan Chase & Co. raised their target price on Repligen from $190.00 to $200.00 and gave the stock an "overweight" rating in a research report on Friday, February 21st. HC Wainwright restated a "buy" rating and set a $180.00 price target on shares of Repligen in a research note on Friday, February 21st. Finally, Royal Bank of Canada increased their price objective on shares of Repligen from $203.00 to $205.00 and gave the stock an "outperform" rating in a research note on Friday, February 21st. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $181.00.
Check Out Our Latest Analysis on Repligen
Repligen Company Profile
(
Free Report)
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.
See Also
Before you consider Repligen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Repligen wasn't on the list.
While Repligen currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
